Stay updated on Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Sign up to get notified when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page

  1. Check
    4 days ago
    No Change Detected
  2. Check
    11 days ago
    Change Detected
    Summary
    The website has added new features for data download options, while several key government health-related links and extensive data field descriptions have been removed.
    Difference
    14%
    Check dated 2024-11-23T03:46:32.000Z thumbnail image
  3. Check
    19 days ago
    Change Detected
    Summary
    New resources have been added, including links to HHS, NIH, NLM, NCBI, and USA.gov, enhancing the website's informational offerings.
    Difference
    0.7%
    Check dated 2024-11-15T18:46:13.000Z thumbnail image
  4. Check
    26 days ago
    Change Detected
    Summary
    The website has been updated to version v2.12.2, introducing new download options in various file formats and enhanced data field selection for studies.
    Difference
    16%
    Check dated 2024-11-08T14:24:28.000Z thumbnail image
  5. Check
    33 days ago
    Change Detected
    Summary
    The website has been updated from version 2.12.0 to 2.12.1.
    Difference
    0.3%
    Check dated 2024-11-01T10:16:35.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    The website has been updated from version 2.11.2 to 2.12.0, indicating a new release with potential enhancements or features.
    Difference
    0.7%
    Check dated 2024-10-25T00:19:43.000Z thumbnail image
  7. Check
    62 days ago
    Change Detected
    Summary
    The website has been updated from version 2.11.0 to 2.11.2, indicating new features or improvements.
    Difference
    0.3%
    Check dated 2024-10-03T04:24:43.000Z thumbnail image

Stay in the know with updates to Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Subcutaneous vs. Intravenous Daratumumab in Myeloma Clinical Trial page.